Skip to main content
. Author manuscript; available in PMC: 2019 Oct 1.
Published in final edited form as: Brain Behav Immun. 2018 May 28;73:364–374. doi: 10.1016/j.bbi.2018.05.021

Figure 2. TRIFKO mice have attenuated acute sickness behavior in response to systemic LPS exposure.

Figure 2

A) Cumulative food intake after 250 µg/kg IP LPS treatment. Veh = vehicle treatment (BSA/saline). ΦΦ = p<0.01 for WT LPS vs. TRIFKO LPS in Bonferroni post hoc comparisons at 6 hrs after injection, ΦΦΦ = p<0.001 for WT LPS vs. TRIFKO LPS in Bonferroni post hoc comparisons at 12, 24, 36, and 48 hrs after injection. B) Body weight change after 250 µg/kg IP LPS treatment. BW = body weight. ΦΦΦ = p<0.001 for WT LPS vs. TRIFKO LPS in Bonferroni post hoc comparisons at 12, 24, 36, and 48 hrs after injection. N = 5–7/group. C) Plasma corticosterone measurement 4 hrs after 250 µg/kg IP LPS treatment. N = 5/group. *** = p<0.001 for Bonferroni post hoc comparisons comparing saline-treated animals to LPS-treated animals within the same genotype, ### = p<0.001 for interaction effect in Two-way ANOVA. D) Expression of inflammatory cytokine genes in the hypothalamus 6 hrs after 250 µg/kg IP LPS treatment. All data are analyzed from ΔCt values and normalized to WT saline group. ** = p<0.01, *** = p<0.001 for Bonferroni post hoc comparisons comparing saline-treated animals to LPS-treated animals within the same genotype. # = p<0.05, ## = p<0.01, ### = p<0.001 for interaction effect in Two-way ANOVA. N = 3–4/group. One outlier was removed in the TRIFKO LPS groups due to complete lack of behavioral response to LPS.